Program
NVX-CoV2373 adjuvated lipid nanoparticle
Also written as “NVX-CoV2373”, “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)” and “NVX-Cov2373”.
Its studies are mostly in COVID-19 · Severe Acute Respiratory Syndrome, led by 4 companies.
Drug pageNVX-CoV2373 adjuvated lipid nanoparticle: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novavaxits history only | 120 open or running | phase 4since Oct 4, 2024 | Apr 24, 2020 | none ahead |
| Takedaits history only | 20 open or running | phase 3since Mar 27, 2022 | Jan 14, 2021 | none ahead |
| Cogna Technology Solutions | 10 open or running | phase 3since Feb 18, 2022 | Feb 18, 2022 | none ahead |
| Sanofiits history only | 11 open or running | phase 4since Sep 30, 2026 | Sep 30, 2026 | Nov 26, 2026phase 4 · NCT07861542 |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Cogna Technology Solutions only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 18, 2022First study: phase 3 study in Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)First studyNCT05249816 · 1,000 enrolled · United Arab Emirates
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
Studies
The one study Cogna Technology Solutions leads. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05249816Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) · United Arab Emirates | 3 | Completed | May 4, 2023 | 1,000 |
How it is read
Names in the registry
- “NVX-CoV2373”, 3 entries
- “SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period)”, 2 entries
- “NVX-Cov2373”, 2 entries
- “TAK-019”, 2 entries
- “Omicron Subvariant-Based SARS-CoV-2 Recombinant Spike Vaccine Adjuvanted With Matrix-M”, 1 entry
Conditions, from the studies’ own filings
- COVID-19, 13 studies
- Severe Acute Respiratory Syndrome, 3 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.